Dr. Frank Sistare Joins Taconic Biosciences' Scientific Advisory Board
Rensselaer, NY — October 17, 2019 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the addition of Frank Sistare, PhD to its Scientific Advisory Board (SAB). Dr. Sistare joins existing SAB members Andrew Goodman, PhD, David Hill, PhD, and Robert Rosenthal, PhD.
The SAB will continue to collaborate with Taconic's management in providing scientific insight and guidance on the evolution of the company's product and service portfolio. Dr. Sistare's extensive career and expertise in the field of toxicology complements the standing board members.
The SAB members provide expertise in microbiome, oncology, and toxicology spaces helping to drive innovation in these and other research areas.
"Animal models continue to evolve as critical tools for drug discovery efficacy and safety testing applications. We welcome Dr. Sistare and his deep experience as Taconic continues developing solutions that are more precise and relevant to human clinical outcomes," shared Nancy J. Sandy, chief executive officer of Taconic Biosciences.
Dr. Frank Sistare has served for the past 16 years as executive director, associate vice president, and then scientific associate vice president within safety assessment and laboratory animal resources at Merck Research Laboratories. He served previously for 15 years in several leadership and management positions with the laboratory research component of the Food and Drug Administration's Center for Drug Evaluation and Research. Dr. Sistare is a retired captain from the Public Health Service (PHS) Commissioned Corps. He is a recipient of the Merck Presidential Fellowship Award, and has received several PHS Unit Commendations, as well as PHS Meritorious Service, Commendation, and Achievement Awards, and CDER and FDA awards for excellence in laboratory research.
He earned his BS in Pharmacy from the University of Rhode Island, his PhD in Pharmacology at the University of Virginia, and was awarded a postdoctoral PRAT Fellowship at the National Institutes of Health. He has served as President of the Regulatory and Safety Evaluation Specialty Section of the Society of Toxicology, as Co-Director of the Critical Path Institute's Predictive Safety Testing Consortium (PSTC), as Co-Chair of the PSTC Nephrotoxicity Biomarker Working Group, and currently serves as Rapporteur of the International Conference on Harmonization S1 Carcinogenicity Expert Working Group, Chairperson of the PhRMA Clinical and Preclinical Development Committee's Carcinogenicity Key Issue Working Group, and Chairperson of the FNIH Biomarker Consortium's Clinical Kidney Safety Biomarker Qualification Project Team.
Please find information on Taconic's additional SAB members below:
Dr. David Hill has established a successful and extensive career leading the pharmacology departments of many major pharmaceutical companies, including a combined twenty years at Organon and Merck. Dr. Hill's therapeutic expertise includes neuroscience, pain, anesthesia, cardiometabolic disease, and oncology. During his career, Dr. Hill played a pivotal role in directing preclinical animal model programs of various sizes that resulted in many new approved therapeutics. Beyond his scientific expertise, Dr. Hill also brings a keen knowledge of harmonizing internal and outsourced resources to produce both sound scientific and business results. Dr. Hill earned a Bachelor of Science in Applied Biology from Hatfield Polytechnic and PhD in pharmacology from St. Thomas Hospital Medical School.
Dr. Robert J. Rosenthal has more than 30 years of experience relating to companies involved in the development of diagnostics, therapeutics, medical devices, and life sciences tools. He currently serves on the Safeguard Scientifics, Inc. Board of Directors, where he is Chairman of the Capital Management Committee and a member of the Audit Committee and Compensation Committee. Prior to Taconic, Bob's recent executive leadership roles include; Chairman of the Board and Chief Executive Officer of IMI Intelligent Medical Implants AG, a medical technology company that developed a retinal implant system for degenerative disorders; and as President, Chief Executive Officer and a Director of Magellan Biosciences, Inc., a provider of life sciences research tools, which he founded. Bob holds a BS degree from the University of Maryland, an MS from State University of New York, a PhD from Emory University and an Executive MBA from Stanford University. He completed a post-doctoral fellowship at Universität Würzburg, Germany, as a guest scientist of the Alexander von Humboldt Foundation, followed by an additional post-doctoral fellowship at UCLA.
To learn more about Taconic's products and services, please contact Taconic Biosciences at 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immune-oncology mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.
Media Contact:
marketing@taconic.com